Acute myeloid leukaemia (AML) is treatable and potentially curable disease. Signi cant morbidity is related to the prolonged, severe neutropenia resulting from the disease as well as the intensive chemotherapy. e administration of granulocyte -colony stimulating factor (G-CSF) is recommended to reduce the neutropenic period. But the current information and guidelines are insu cient about the most appropriate time to start G-CSF and the optimum duration of treatment after chemotherapy in consolidation phase. is study explores better timing to start G-CSF after completion of chemotherapy in consolidation phase of AML patient. is prospective study was conducted in the department of Haematology, Bangabandhu Sheikh Mujib Medical University among AML patients, who received consolidation chemotherapy (high dose cytarabine).
INTRODUCTION
e global burden from cancer is rising. According to world health organisation (WHO), Bangladesh is experiencing increasing cancer burden with estimated 122,715 new cancer cases in 2012. Haematological malignancies comprise approximately 6.5% of all cancer incidences worldwide in 2012. 1 Hossain et al. published a multi-centre hospital-based retrospective descriptive study of Bangladesh over 5000 con rmed haematological cancer cases in between January 2008 to December 2012. 2 In this study Acute Myeloid Leukaemia was most frequent (28.3%) with a median age of 35 years.
Acute myeloid leukaemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukaemia a ecting adults, and its incidence increases with age. 3 AML is a treatable and potentially curable disease with intensive chemotherapy accompanied by recent improvements in supportive care. 4 In a recent Cancer and Leukaemia Group B (CALGB) study, 44% of patients less than 60 years of age who achieved complete remission (CR) with standard cytosine arabinoside (Ara-C) and daunorubicin chemotherapy and subsequently received up to four courses of post remission consolidation chemotherapy with high-dose cytosine arabinoside (HiDAC), were estimated to remain in disease free condition at 5 years. 5 Barriers to achieve higher rate of cure in AML include drug-resistant leukaemia, extramedullary toxicity from chemotherapeutic drugs, and prolonged pancytopenia due to ablative chemotherapy. 6 Remission induction and consolidation treatment for acute myeloid leukaemia (AML) is associated with considerable morbidity and mortality. 7, 8 A signi cant morbidity is related to the prolonged, severe neutropenia resulting from the disease as well as the intensive chemotherapy. e outcome of treatment is dependent, in part, on the ability of patients to tolerate the myelosuppression and its consequences. 9 Incidence of febrile neutropenia in consolidation phase is more than 85%. 10 e current ASCO guidelines justi ed the administration of colony stimulating factor (CSF) in clinical settings where the expected risk of su ering from febrile neutropenia (FN) is approximately 20%. 11 G-CSF is a naturally occurring cytokine that stimulates the proliferation and di erentiation of haemopoietic stem and progenitor cells committed to the neutrophil and granulocyte lineages. Fully di erentiated neutrophilic granulocytes are functionally activated by G-CSF. 12 Two forms of recombinant human G-CSF are available for clinical use -lgrastim and lenograstim. Both are produced by recombinant DNA technology. Filgrastim is produced in Escherichia coli whereas lenograstim is derived from Chinese hamster ovary cells. Available data do not suggest a clinically remarkable di erence between lgrastim and lenograstim in chemotherapy-induced neutropenia and the mobilisation of peripheral blood progenitor cells in patients and healthy donors. 13 Depth and duration of neutropenia correlate with the risk and severity of infection. 14 So reducing the frequency and severity of neutropenia is considered a clinically relevant end point.
is premise has been used to justify the administration of G-CSF. But the current data is not su cient to indicate regarding the most appropriate time to start G-CSF and the optimum duration of treatment after consolidation chemotherapy of AML patient to reduce neutropenic events. 15 
MATERIALS AND METHODS
is is a prospective observational study. is study was done at the department of Haematology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh. Study period for this study was from October, 2014 to March, 2016. Study population were the AML patients in Complete Remission admitted to Haematology Department for consolidation phase with high dose Cytarabine (HiDAC, 3000 mg/m 2 ). AML patients, who completed consolidation chemotherapy with HiDAC, satisfying inclusion and exclusion criteria, were included to this study. Confounding variables such as antibiotic therapy also were matched. Samples were grouped into two arms. Arm-A (ANC> 1000/cmm) received prophylactic G-CSF and Arm-B (ANC <1000/cmm) received G-CSF during neutropenia. Filgrastim was used as G-CSF and daily dose was 300 micrograms subcutaneously; and it will be continued up to neutrophil recovery (Absolute neutrophil count 1 9 /L for 2 consecutive days). Purposive sampling was done. AML patients who have completed consolidation chemotherapy with HiDAC, aged between 18-60 years, Total WBC count 4000-11000/cmm and ANC>1000/cmm in peripheral blood before starting chemotherapy were taken. Informed written consent by the patient/party was taken. Patients with Acute promyelocytic leukaemia (AML M 3 ) and body weight <35kg or >80 kg were excluded from this study. Statistical analysis was done by parametric (t test) test and appropriate using computer based SPSS (21) Program.
RESULTS
During 17 months study period, since October 2014-March 2016, a total number of 19 patients who achieved complete remission after induction chemotherapy and then received consolidation chemotherapy with high dose cytarabine were analyzed. During each consolidation phase after nishing last dose of chemotherapy these patients were treated with G-CSF to reduce neutropenic period, neutropenic fever and hospital stay. G-CSF was given at least 72 hours later of last dose chemotherapy. Six (6) patients received prophylactic G-CSF (Arm-A) before development of neutropenia while ANC>1000/cmm and thirteen (13) patients received delayed G-CSF (Arm-B) during neutropenic period while ANC<1000/cmm. After then outcomes were observed. Out of the 19 patients in the study, maximum was male (63.16%) and remaining (36.84%) patients were female. Male female ratio was 1. (Table I) . First day of G-CSF application was counted from 1 st day of chemotherapy. Mean (±SD) 1 st day of G-CSF application in Arm-A was 9.5 th day (±1.22) and Arm-B 14.5 th day (±2.96). P value was 0.001 and signi cant as p<0.05 (Table II) . Mean (±SD) of G-CSF requirement in Arm-A was 11.5 (±3.56) and Arm-B 5.92 (±2.69). P value was 0.0014 and signi cant as p<0.05 (Table III) . First day of neutropenia was counted from 1 st day of chemotherapy. Mean (±SD) 1 st day of neutropenia which developed after chemotherapy in Arm-A was 11 th day (±1.55) and Arm-B 11.46 th day (±2.57). P value was 0.6914 and this value was not signi cant as p>0.05 (Table  IV) . Duration of ANC recovery was counted from 1 st day of neutropenia after chemotherapy to neutrophil count recovery. Mean (±SD) days needed to recover in Arm-A was 10 days (±3.85) and Arm-B 9.85 days (±2.23). P value was 0.913 and this value was not signi cant as p>0.05 (Table V) . Out of the 6 patients in Arm-A 3 (50%) patients developed neutropenic fever and out of 13 patients in Arm-B 7 (53.85%) patients developed neutropenic fever (Table VI) . Mean (±SD) duration of neutropenic fever in Arm-A was 1.33 days (±1.97) and Arm-B 1.38 days (±2.23). P value was 0.965 and this value was not signi cant as p>0.05 (Table VII) . Duration of hospitalization was counted from rst day of chemotherapy to neutrophil count recovery. Mean (±SD) duration of hospital stay in Arm-A was 20 days (±3.35) and Arm-B 20.3 days (±1.89). P value was 0.259 and this value was not signi cant as p>0.05 (Table VIII) . Mean (±SD) of platelet concentrate requirement in Arm-A was 11.83 (±9.22) and Arm-B 7.77 (±5.43). P value was 0.2405 and this value was not signi cant as p>0.05 (Table IX) . Mean (±SD) requirement of red cell concentrate in Arm-A was 1.83 (±1.60) and Arm-B 1.46 (±1.05). P value was 0.550 and this value was not signi cant as p>0.05 (Table  X) . ere was no death both in Arm-A and Arm-B.
DISCUSSION
is study was done to understand better timing of G-CSF starting after chemotherapy in consolidation phase of adult AML patients.
In this study, di erences between two arms in ANC of G-CSF application by 898/cmm (1170.50/cmm vs 272.6/cmm; P=<0.0001); timing di erence of G-CSF application by 5 days (9.5 th day vs 14.5 th day; P=0.001); and total need of G-CSF by 5.6 (11.5 G-CSF vs 5.92 G-CSF; P=0.0014); were signi cant. e outcomes such as neutropenic period (10 days vs 9.85 days; P=0.91); duration of febrile days during neutropenia (1.33 days vs 1.38 days; P=0.96); hospital stay (20 days vs 20.3 days; P=0.259); and rst day of neutropenia (11th days vs 11.46 days; P=0.69) revealed no statistically signi cant di erences.
Moreover, mean platelet concentrates (11.83 units vs 7.77 units) and mean red cell concentrates (1.83 units vs 1.46 units) requirement also were more in prophylactic G-CSF group than delayed G-CSF group. Comparison of above ndings between di erent age and sex groups were not focused as it failed to reveal any statistically signi cant value.
Above ndings also correlate with the study of Marie VLT et al. 16 Red cell concentrates and platelet concentrates requirement were more in prophylactic group probably due to more use of G-CSF. ese ndings correlate with the study of Papaldo et al. 18 , Wexler LX and Stroncek DF et al. 19 Papaldo et al. reported on the e ects of G-CSF on haemoglobin in 506 patients with stage I-II breast cancer who received adjuvant epirubicin and cyclophosphamide (EC) at 120 mg/m² and 600 mg/m². Overall the study showed that anaemia was higher in the G-CSF group than in the controls (38.8% vs. 26.2%, P<0.005). 18 In the study of Wexler LX thirty-seven newly diagnosed cases age 1 to 25 years were randomized to receive 18 cycles of chemotherapy alone or with GM-CSF. GM-CSF was associated with more severe and protracted thrombocytopenia; median platelet nadir 29,500/micro litre (range 3,000 to 288,000) vs. 59,000/micro litre (range 3,000 to 309,000), P < 0.0001; median time to recovery (> 75,000/microlitre) 16.0 days (range, 0 to 61) vs. 14.0 days (range 0 to 38), P < 0.0001(signi cant). 19 In the study of Stroncek DF et al. no signi cant decrease in platelet counts was noted after administering G-CSF for 5 days, but individuals who received 10 days of G-CSF showed a close to 30% decrease from pre treatment platelet values prior to the aphaeresis. 20 Above discussion gives information that prophylactic G-CSF (i.e G-CSF started before development of neutropenia) failed to show better outcomes than delayed G-CSF in consolidation phase of AML.
CONCLUSIONS
In the light of the discussion, the following conclusions and recommendations are made to understand the better timing to start G-CSF after chemotherapy in consolidation phase of AML patient.
Di erent guidelines recommended for using G-CSF in consolidation phase of AML and it can be started 24-72 hours after last dose of chemotherapy. is study evaluated the timing to start G-CSF on duration of G-CSF use, duration of hospitalization, duration of neutropenia and number of febrile days in AML patients.
Both prophylactic G-CSF group and delayed G-CSF group showed no statistically signi cant di erence on neutropenic period, febrile days, neutrophil recovery, hospitalization, red cell concentrate and platelet concentrate transfusion. Rather early administration of G-CSF associated with more use of G-CSF as well as more need of red cell concentrate and platelet concentrate transfusion, which in turn increase the total treatment cost.
In conclusion, administration of G-CSF can be delayed to nine days or upto 270/cmm of ANC after the end of chemotherapy without a prolonged duration of neutropenia or other adverse e ects. Prospective, controlled studies are needed to support these ndings.
